These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35790816)

  • 1. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.
    Reiter A; Gotlib J; Álvarez-Twose I; Radia DH; Lübke J; Bobbili PJ; Wang A; Norregaard C; Dimitrijevic S; Sullivan E; Louie-Gao M; Schwaab J; Galinsky IA; Perkins C; Sperr WR; Sriskandarajah P; Chin A; Sendhil SR; Duh MS; Valent P; DeAngelo DJ
    Leukemia; 2022 Aug; 36(8):2108-2120. PubMed ID: 35790816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
    Pilkington H; Smith S; Roskell N; Iannazzo S
    Future Oncol; 2022 Apr; 18(13):1583-1594. PubMed ID: 35114819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
    Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
    Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avapritinib for advanced systemic mastocytosis.
    Gotlib J; Reiter A; DeAngelo DJ
    Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
    Gotlib J; Reiter A; Radia DH; Deininger MW; George TI; Panse J; Vannucchi AM; Platzbecker U; Alvarez-Twose I; Mital A; Hermine O; Dybedal I; Hexner EO; Hicks LK; Span L; Mesa R; Bose P; Pettit KM; Heaney ML; Oh ST; Sen J; Lin HM; Mar BG; DeAngelo DJ
    Nat Med; 2021 Dec; 27(12):2192-2199. PubMed ID: 34873345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
    DeAngelo DJ; Radia DH; George TI; Robinson WA; Quiery AT; Drummond MW; Bose P; Hexner EO; Winton EF; Horny HP; Tugnait M; Schmidt-Kittler O; Evans EK; Lin HM; Mar BG; Verstovsek S; Deininger MW; Gotlib J
    Nat Med; 2021 Dec; 27(12):2183-2191. PubMed ID: 34873347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avapritinib for Systemic Mastocytosis.
    Bose P; Verstovsek S
    Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avapritinib in the Treatment of Systemic Mastocytosis: an Update.
    Below S; Michaelis LC
    Curr Hematol Malig Rep; 2021 Oct; 16(5):464-472. PubMed ID: 34580817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib.
    Kudlaty E; Perez M; Stein BL; Bochner BS; Kuang FL
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2534-2536. PubMed ID: 33677080
    [No Abstract]   [Full Text] [Related]  

  • 11. Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.
    Sriskandarajah P; McLornan DP; Oni C; Wilson AJ; Woodley C; Ciesielska M; Raj K; Dillon R; Ethell M; Chacko J; Orchard K; Radia DH
    Curr Res Transl Med; 2023; 71(3):103398. PubMed ID: 37331225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
    Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby-Olsen S; George TI; Panse J; Alvarez-Twose I; Radia DH; Tashi T; Bulai Livideanu C; Sabato V; Heaney M; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Pongdee T; Barete S; Ustun C; Schwartz L; Ward BR; Schafhausen P; Vadas P; Bose P; DeAngelo DJ; Rein L; Vachhani P; Triggiani M; Bonadonna P; Rafferty M; Butt NM; Oh ST; Wortmann F; Ungerstedt J; Guilarte M; Taparia M; Kuykendall AT; Arana Yi C; Ogbogu P; Gaudy-Marqueste C; Mattsson M; Shomali W; Giannetti MP; Bidollari I; Lin HM; Sulllivan E; Mar B; Scherber R; Roche M; Akin C; Maurer M
    NEJM Evid; 2023 Jun; 2(6):EVIDoa2200339. PubMed ID: 38320129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy.
    Huang X; Pomicter AD; Ahmann J; Qiao Y; Chen OS; George TI; Cruz-Rodriguez N; Guru SA; Marth GT; Deininger MW
    Blood Cancer J; 2024 Oct; 14(1):179. PubMed ID: 39402020
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
    von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
    BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
    Reiter A; George TI; Gotlib J
    Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.
    Sheikh IN; AlQahtani S; Yin CC; McCall D; Cuglievan B; Ragoonanan D; Connors JS; Gibson A; Nunez C; Roth M; Ohanian M; Borthakur G; Garcia MB
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30898. PubMed ID: 38291730
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
    Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
    Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of avapritinib in refractory aggressive systemic mastocytosis: a single-patient case.
    Szudy-Szczyrek A; Juda A; Kokoć A; Krupski W; Szumiło J; Hus M
    Pol Arch Intern Med; 2023 May; 133(5):. PubMed ID: 36994901
    [No Abstract]   [Full Text] [Related]  

  • 20. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis.
    Cavazos K; Eswaran S; Maidlow C; Keklik Karadag F; Idilman R; Idilman I; Miller I; Shammo J; Reau N; Ustun C
    Blood Adv; 2022 Oct; 6(20):5630-5633. PubMed ID: 35839085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.